Equities research analysts at Morgan Stanley assumed coverage on shares of Personalis (NASDAQ:PSNL) in a research note issued to investors on Monday, Marketbeat.com reports. The brokerage set an “overweight” rating and a $28.00 price target on the stock. Morgan Stanley’s target price suggests a potential upside of 24.06% from the stock’s previous close.
Separately, Bank of America reissued a “buy” rating and issued a $78.00 price objective on shares of Citigroup in a research note on Monday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $28.25.
Shares of NASDAQ:PSNL opened at $22.57 on Monday. Personalis has a 52-week low of $21.73 and a 52-week high of $31.88.
Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.
Read More: Investing in Blue-Chip Stocks
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.